Autor(es): Günther, G ; van Leth, F ; Altet, N ; Dedicoat, M ; Duarte, R ; Gualano, G ; Kunst, H ; Muylle, I ; Spinu, V ; Tiberi, S ; Viiklepp, P ; Lange, C
Data: 2015
Identificador Persistente: http://hdl.handle.net/10216/114669
Origem: Repositório Aberto da Universidade do Porto
Assunto(s): Multidrug-resistant tuberculosis
The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).
